Both groups promise that their vaccine is “still effective” against the new strain of the virus while developing a “specific” product whose marketing could begin by March 2022.
Posted
Update
Reading time : 1 min.
Faced with concerns related to the new Omicron variant, the laboratories want to reassure. The vaccine against Covid-19 developed by the companies Pfizer and BioNTech is “always effective” against the Omicron variant after “three doses”, assured the two groups, Wednesday, December 8, in a joint statement (in English). However, the two companies wish to finalize a vaccine adapted to the variant. “by March”, they add.
According to studies carried out by the two companies, “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it is clear from this preliminary data that protection is improved with a third dose of our vaccine.”, notes Albert Bourla, President and CEO of Pfizer.
Pfizer and BioNTech will also “continue the development of a vaccine specific to the Omicron variant”, hoping “make it available by March in case an adaptation is necessary”.